Fresh analysis reveals that individuals who come off popular slimming jabs like semaglutide or tirzepatide can put back on shed pounds at a significantly accelerated pace than those who end conventional diet and exercise regimens.
Findings released in a major health publication shows that while overweight individuals often shed a large proportion of their total mass while using the jabs, the weight returns at an average rate of 0.8 kg per month upon discontinuation.
"Individuals using such drugs need to be aware of the risk of rapid weight regain when the medication is stopped," cautioned researcher Dr. Susan Jebb.
Such speed of recovery means a reversion to starting mass in about a year and a half.
Comparing Treatments
The study, which reviewed 37 of trials involving thousands of participants, contrasted the outcomes of GLP-1 agonists with conventional dieting.
Scientists emphasize that individuals who lose weight through lifestyle changes alone typically see a less rapid weight regain—approximately 0.1 kg a month—after stopping.
Explaining the Rapid Rebound
Doctors suggest the mode of action of the injections accounts for the heightened weight return.
These medications imitate a body's own chemical called glucagon-like peptide-1, which moderates appetite.
"Long-term administration of the hormone levels far above than the body's typical production could lead to the body to generate a reduced amount of its own natural hormone, and could diminish responsiveness to its effects," said Dr. Adam Collins, a nutrition expert.
"Withdrawal of this hormone supplement means appetite is unsuppressed, making binge eating a significant risk."
A Chronic Disease?
Medical guidelines recommend the injections for individuals with weight-linked health risks, alongside prescribed diet and exercise modifications.
Many experts say that, due to the high risk of weight regain, the therapy might need to be ongoing.
This perspective is echoed by pharmaceutical companies, who note that the results "emphasize the persistent character of obesity," similar to managing conditions like hypertension.
User Accounts
Users who have come off the medication report a intense resurgence of appetite.
"It was like something that goes on and I was suddenly extremely hungry," described one woman.
This difficulty is worsened if users have not developed sustainable lifestyle or habit modifications during treatment.
Significant Use
Survey data suggest that millions of adults in the UK have tried these injections in the last 12 months, with interest remaining high.
- Adoption is higher among females than men.
- The middle-aged demographic shows the greatest level of interest.
- Many access the drugs through private prescriptions rather than public health services.
Finally, clinicians stress that while the jabs are potent agents for weight loss, they are not a permanent solution and long-term success hinges on ongoing lifestyle changes.
